“Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”

Mardian, Yan; Yano, Yoshihiko; Ratnasari, Neneng; Choridah, Lina; Wasityastuti, Widya; Setyawan, Nurhuda Hendra; Hayashi, Yoshitake

doi:10.1186/s12876-019-1152-4

Cited by 23 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 6 to stratify patients into those with low and high SMD. In the remaining 17 studies assessing SMD, threshold values used ranged from ≤22.0 HU 23 to ≤44.4 HU 24 , 25 , 26 in male patients and ≤23.5 23 to ≤39.3 24 in female patients. Similar to their analysis of SMI, Aleixo et al reported the proportion of patients with low SMD across multiple thresholds.…”

Section: Resultsmentioning

confidence: 99%

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

McGovern

Dolan

Horgan

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic tool in those with cancer. A range of pre‐defined thresholds currently exist within the literature to define low skeletal muscle mass and density. The aim of the present systematic review was to assess the prevalence of low skeletal muscle index (SMI) and density (SMD) within the literature, across a range of common solid tumours. Methods A systematic search of PubMed was carried out to identify studies reporting CT analysis of SMI and SMD in patients with colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast, and lung cancer. The type of cancer, whether curative or non‐curative disease, the anthropomorphic parameter studied, threshold used to define low SMI and SMD, and the prevalence of these anthropomorphic measurements within the population were recorded. Results Of the 160 studies included, 156 reported an assessment of SMI and 35 reported assessment of SMD. The median prevalence of low SMI was 43% (30.1–57.1) and low SMD 49.4% (31.7–58.5) across the entire cohort. There was little variation in the prevalence of low SMI and SMD when studies were divided into curative and non‐curative cohorts—40.7% (27.5–51.3) vs. 48.4% (30.9–60.1) and 37.8% (32.2–52.2) vs. 55.3% (38.5–64.7) respectively. When divided into colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast and lung cancers, similar prevalence of low SMI (46.0% %, 49.8%, 35.7%, 41.1%, 32.3%, 34%, and 49.5%) and low SMD were also observed (52.1%, 54.3%, 71.2%, 56.8%, 55.3%, and 52.6%). This was maintained when studies were stratified into cohorts by threshold used—low SMI (Martin 48.9%, Prado 49.9%, and Others 36.0%) and low SMD (Martin 52.4% and Others 48.6%). Conclusions Low SMI and SMD are endemic across a range of cancer types and disease stage, challenging pre‐existing dogma of the determinants of prevalence.

show abstract

Section: Resultsmentioning

confidence: 99%

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

McGovern

Dolan

Horgan

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…In patients with cirrhosis awaiting liver transplantation (LT), sarcopenia has been shown to be a significant risk factor for waitlist mortality, postoperative complications, and post-LT death 8 – 10 . Similarly, it has been shown that sarcopenia increases 1-year mortality after surgical resection of hepatocellular carcinoma (HCC) 11 and can predict long-term survival in patients with HCC 12 .…”

Section: Introductionmentioning

confidence: 99%

Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure

Kong

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Sarcopenia is a well-recognized factor affecting the prognosis of chronic liver disease, but its impact on acute decompensation underlying chronic liver disease is unknown. This study evaluated the impact of sarcopenia on short-term mortality in patients with acute-on-chronic liver failure (ACLF). One hundred and seventy-one ACLF patients who underwent abdominal CT between 2015 and 2019 were retrospectively included in this study. Skeletal muscle index at the third lumbar vertebrae (L3-SMI) was used to diagnose sarcopenia.The ACLF patients in this study had a L3-SMI of 41.2 ± 8.3 cm2/m2 and sarcopenia was present in 95/171 (55.6%) patients. Body mass index (BMI), cirrhosis, and higher serum bilirubin were independently associated with sarcopenia. Following multivariate Cox regression analysis, cirrhosis (hazard ratio (HR) 2.758, 95%CI 1.323–5.750), serum bilirubin (HR 1.049, 95%CI 1.026–1.073), and international normalized ratio (INR) (HR 1.725, 95%CI 1.263–2.355) were associated with 3-month mortality (P < 0.05), whereas L3-SMI and sarcopenia were not. A subgroup analysis of the factors related to sarcopenia showed that sarcopenia was still not predictive of short-term outcome in ACLF patients. L3-SMI and sarcopenia are not associated with short-term mortality in patients with ACLF.

show abstract

“…Moreover, the moderate risk of bias was determined to be due to study attrition in eight studies, adjustment for other prognostic factors in eight studies, statistical analysis and reporting in five studies. In general, of the 42 included studies, 34 studies were at an overall low risk of bias ( 14 – 16 , 22 – 25 , 28 – 32 , 34 , 35 , 37 , 39 – 44 , 46 , 47 , 49 – 59 ), while eight were at an overall moderate risk of bias ( 26 , 27 , 33 , 36 , 38 , 45 , 48 , 60 ).…”

Section: Resultsmentioning

confidence: 99%

Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis

Jiang

Wang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

BackgroundSarcopenia, characterized by the loss of muscle mass, strength, and physical ability, occurs with aging and certain chronic illnesses such as chronic liver diseases and cancer. Sarcopenia is common in liver cirrhosis and hepatocellular carcinoma (HCC). Previous reports of association between sarcopenia and prognosis of HCC have been inconsistent. Therefore, the present systematic review and meta-analysis aimed to investigate the impact of sarcopenia on the survival of patients with HCC.MethodsA systematic literature search was conducted using PubMed, EMBASE, and Web of Science electronic databases from inception to May 1, 2022. We included retrospective or prospective studies investigating the association between sarcopenia and overall survival (OS) and/or progression free survival (PFS) of HCC. We applied the Quality in Prognosis Studies (QUIPS) instrument to evaluate the risk of bias and quality of included studies. The primary and secondary outcomes were the associations of sarcopenia with OS and PFS, respectively, expressed by a pooled hazard ratio (HR) and corresponding 95% confidence interval (CI). Subgroup analysis and sensitivity analysis were performed. We further evaluated the publication bias by the funnel plot and Begg’s test.ResultsA total of 42 studies comprising 8,445 patients were included. The majority of included studies were at an overall low risk of bias. The pooled prevalence of sarcopenia was 39% (95% CI: 33–45%) (n = 8,203). Sarcopenia was associated with an increased risk of shorter OS, with a pooled adjusted HR of 1.84 (95% CI: 1.62–2.09). An independent association between sarcopenia and reduced PFS was observed (HR = 1.33, 95% CI: 1.12–1.56).ConclusionThe prevalence of sarcopenia was approximately 39% among patients with HCC. Sarcopenia was independently associated with reduced OS and PFS in HCC irrespective of treatment modalities. It is imperative that interventions aimed at alleviating sarcopenia and restoring muscle mass be implemented in order to improve the survival of patients with HCC.Systematic review registration[https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022337797], identifier [CRD42022337797].

show abstract

“Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”

Cited by 23 publications

References 31 publications

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure

Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis

Contact Info

Product

Resources

About